Current Neuropharmacology
ISSN 1570-159x · Bentham Science Publishers · United Arab Emirates · active 1969–2026
Flagged for closer checking
Publisher listed on Beall's archive (frozen 2017). Cross-check with DOAJ and Think.Check.Submit before submission.
This is a screening signal, not a verdict. How this check works.
Metrics
- Scimago quartile (2025)
- Q1
- Cites per paper (2y)
- 2.8
- SJR
- 1.642
- h-index
- 141
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 1 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Current Neuropharmacology is Q1 in all 6 of its subject categories.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Neurology | Q1 | #23 of 204 |
| Pharmacology (medical) | Q1 | #25 of 286 |
| Pharmacology | Q1 | #35 of 339 |
| Neurology (clinical) | Q1 | #51 of 406 |
| Psychiatry and Mental Health | Q1 | #63 of 605 |
| Medicine (miscellaneous) | Q1 | #221 of 2,517 |
- Cites per document (2 years, Scopus)
- 6.36
- Documents indexed in 2025 (Scopus)
- 192
OpenAlex counts about 2.8 citations per paper over two years; Scopus, through Scimago, counts 6.36 per document. The two databases index different journals, documents and citations, so the figures differ. Neither is a Clarivate Journal Impact Factor.
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Current Neuropharmacology a predatory journal?
Our screening flags Current Neuropharmacology as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.
Is Current Neuropharmacology indexed in Scopus or Web of Science?
Per our venue index, Current Neuropharmacology appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Current Neuropharmacology?
Papers in Current Neuropharmacology are cited about 2.8 times each within two years of publication, and Scimago places it in Q1, with an h-index of 141. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Current Neuropharmacology (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Current Neuropharmacology is Q1 in all 6 of its subject categories. By category: Neurology: Q1, #23 of 204; Pharmacology (medical): Q1, #25 of 286; Pharmacology: Q1, #35 of 339; Neurology (clinical): Q1, #51 of 406; Psychiatry and Mental Health: Q1, #63 of 605; Medicine (miscellaneous): Q1, #221 of 2,517. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Neuropharmacology is cited about 2.8 times per paper over two years, with an h-index of 141.
What is the Web of Science (JCR) quartile of Current Neuropharmacology?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Neuropharmacology. The open equivalent is its Scimago quartile, Q1, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Current Neuropharmacology open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Ready to submit? Tools for your next paper
Similar venues
Compare it with its peers: Ranked Cellular and Molecular Neuroscience journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.